Chemistry:GSK-2849466

From HandWiki

GSK-2849466 is an investigational new drug that is a selective androgen receptor modulator (SARM) that was being developed by GlaxoSmithKline (GSK). This experimental compound reached Phase I clinical trials for the treatment of cachexia and heart failure.[1][2][3] However, as of February 2014, GSK discontinued the development of GSK-2849466 for both indications after completing Phase I studies.[2]

References

  1. ↑ "GSK-2849466". PatSnap. https://synapse.patsnap.com/drug/3a9633b84a284657acaa5a354af919d3. 
  2. ↑ 2.0 2.1 "GSK 2849466". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800036899. 
  3. ↑ "Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials". Expert Opinion on Investigational Drugs 29 (8): 881–891. August 2020. doi:10.1080/13543784.2020.1777275. PMID 32476495. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:GSK-2849466&oldid=4031214"